Acute cardiac care & resuscitation
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock
Main finding · MACE (composite of all-cause death, ischaemic stroke, myocardial infarction, or stent thrombosis)Result — go to the resultWeighted hazard ratio 1.11 95% CI 0.82–1.50Authors' conclusion
In patients with AMI-CS, pretreatment with a P2Y12 inhibitor oral load was associated with an increased risk of major bleeding without benefit on MACE.
Study context
- Population
- Patients hospitalized between 2012 and 2023 with AMI-CS admitted for coronary angiography within 24 h of admission (ACTION-SHOCK cohort)patients with AMI-CS admitted to the catheterization laboratory within 24 h of admission
- Participants
- 421 patients
- Exposure
- Pre-treatment with P2Y12 inhibitor vs no pre-treatment
- Pre-treatmentn = 224
- Outcome
- MACE:
- All-cause death
- Ischaemic stroke
- Myocardial infarction
- Stent thrombosis
- Follow-up
- 30 days
Methodological detailsinverse probability weighting (IPW) approach, consecutive patients
- Inverse probability weighting (IPW) approach
- Consecutive patients
Main finding
As reported in the abstract
Weighted hazard ratio
1.11
95% CI 0.82–1.50
By group
Pre-treatmentvs No pre-treatment
wHR 1.11 (95% CI 0.82–1.50)
Observational data: associations, not effects.
Further findings
Major adverse cardiovascular events (MACE) or major bleeding at 30 days, STEMI/NSTEMI subgroups
- Effect consistent across STEMI/NSTEMI patients
Safety
| Outcome | Pre-treatment | No pre-treatment | wHR (95% CI) | |
|---|---|---|---|---|
| Major bleeding (BARC grade 3, 4, or 5) · 30 daysIPW | 42.2% | 32.3% | 1.48 (1.05–2.08) | |
| 0.512Weighted hazard ratio (log scale) |
Original publication
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock. Eur Heart J Cardiovasc Pharmacother. Published 1 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →